AFFYMAX PARES PARTNERSHIPS FROM SIX TO THREE SINCE JANUARY GLAXO ACQUISITION; GLAXO WELLCOME HAS ACCUMULATED 10 R&D PARTNERSHIPS WITH BIOTECHS
Executive Summary
Affymax's nine-year agreement with American Home Products is the company's largest external R&D partnership to survive the Glaxo acquisition of the research firm. The AHP deal has an "ongoing commitment of research," Affymax CEO Gordon Ringold, PhD, told a Glaxo Wellcome R&D briefing in New York City Nov. 10. Since being acquired by Glaxo earlier this year, the list of outside partners with Affymax has been cut in half. The combinatorial chemistry and screening company had six corporate agreements in place in January.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth